Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX010 psilocybin-assisted psychotherapy for adjustment disorder in people with incurable cancer
ACTRN12624000449538Phase 2Recruiting
- Sponsor
- Psyence
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PEX010 in adjustment disorder (AD) (3 arms), sponsored by Psyence. Primary endpoints: Change in anxiety severity, Safety and tolerability by vital signs and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
PEX010
03
Conditions
adjustment disorder (AD)
Beyond the preview
Go deeper on ACTRN12624000449538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000449538.